XML 53 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
Description of Business and Basis of Presentation - Additional Information (Detail) (USD $)
 0 Months Ended 1 Months Ended 12 Months Ended 275 Months Ended 12 Months Ended 12 Months Ended 0 Months Ended
Dec. 12, 2001
Oct. 31, 2013
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2002
Dec. 31, 2013
Feb. 08, 2012
Dec. 31, 2010
Dec. 31, 2013
At-the-Market Issuance Sales Agreement
Mar. 18, 2013
Maximum
At-the-Market Issuance Sales Agreement
Dec. 31, 2013
Scenario, Forecast
Dec. 31, 2013
Facility Agreement
Maximum
Jul. 01, 2013
Facility Agreement
Maximum
Dec. 12, 2001
PDC
Dec. 12, 2001
AlleCure
Dec. 12, 2001
CTL
Dec. 31, 2013
Senior convertible notes due December 31 2019
Jul. 01, 2013
Senior convertible notes due December 31 2019
Deerfield
Notes Issued in Four Equal Tranches
Tranche
Jul. 01, 2013
Senior convertible notes due December 31 2019
Deerfield
Tranche One
Jul. 01, 2013
Senior convertible notes due December 31 2019
Deerfield
Maximum
Notes Issued in Four Equal Tranches
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                                          
Deficit accumulated during the development stage     $ 2,296,402,000 $ 2,104,912,000     $ 2,296,402,000                            
Goodwill impairment           151,400,000 151,428,000                            
Cash flow from operation since inception     (128,732,000) (119,860,000) (123,837,000)   (1,724,993,000)                            
Cash and cash equivalents     70,790,000 61,840,000 2,681,000   70,790,000   66,061,000                        
Available borrowings under loan agreement     30,100,000       30,100,000                            
Maximum available amount of credit facility under covenant restrictions                         25,000,000 25,000,000              
Number of Unit Sold in an Underwritten public offering               35,937,500                          
Underwritten public offering               86,300,000                          
Warrant to purchase of a share of common stock               0.6                          
Warrants outstanding     32,843,733       32,843,733                            
Proceeds from warrant exercises   89,700,000 94,147,000       94,147,000         47,300,000                  
Aggregate offering price of common stock under agreement                     50,000,000                    
Sales of common stock under the ATM Agreements             3,900,000     48,900,000                      
Debt facility principal amount                                   120,000,000 160,000,000 40,000,000  
Number of equal tranches                                     4    
Debt facility periodic principal amount                                     40,000,000    
Proceeds from sale of financial instrument                                         90,000,000
Debt facility initial amount                                       40,000,000  
Percentage of ownership                             76.00% 59.00% 69.00%        
In-process research and development costs 19,700,000           19,726,000                            
Goodwill $ 151,400,000